Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Increased by KBC Group NV

KBC Group NV boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 34.8% in the third quarter, Holdings Channel.com reports. The firm owned 2,632 shares of the company’s stock after purchasing an additional 679 shares during the period. KBC Group NV’s holdings in Apellis Pharmaceuticals were worth $76,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Assenagon Asset Management S.A. raised its position in Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares in the last quarter. Iron Triangle Partners LP acquired a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth $32,329,000. Fiera Capital Corp raised its holdings in shares of Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares during the last quarter. Finally, Redmile Group LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter valued at $9,111,000. Institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

APLS has been the topic of several recent research reports. The Goldman Sachs Group cut their target price on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird cut their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Wells Fargo & Company decreased their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Wedbush lifted their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Finally, HC Wainwright decreased their price objective on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $30.77 on Friday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a 50-day moving average of $29.06 and a 200-day moving average of $35.79. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $73.80. The company has a market capitalization of $3.83 billion, a price-to-earnings ratio of -14.85 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. During the same quarter in the prior year, the business earned ($1.17) EPS. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The trade was a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).